Endevica Bio has launched a new spin-off company, Abisati, to accelerate its obesity candidate into clinical trials.
The candidate, 710GO, is a peptide spun out of Endevica Bio’s platform of experimental drugs. Abisati aims to initiate a Phase I trial of the candidate in the second half of 2025, and the company will exclusively exist to bring 710GO to the market.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,